Last Updated : October 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Active | |||
Ferriprox | deferiprone | Transfusional iron overload | Reimburse with clinical criteria and/or conditions | Complete | ||
Ferriprox | Deferiprone | Transfusional iron overload | List with clinical criteria and/or conditions | Complete | ||
Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | ||
Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | ||
Fibristal | Ulipristal acetate | Uterine fibroids | List with criteria/condition | Complete | ||
Finacea | Azelaic acid | Rosacea | List | Complete | ||
Firazyr | icatibant | Acute attacks of hereditary angioedema | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Firazyr | Icatibant | Hereditary angioedema | List with clinical criteria and/or conditions | Complete | ||
Firdapse | amifampridine phosphate | Lambert-Eaton Myasthenic Syndrome, adults | Reimburse with clinical criteria and/or conditions | Complete |